FDA clearance is permission to sell. It is not a reason anyone will buy. The work that decides your commercial fate starts the day after the letter lands.

I've watched this scene play out more times than I can count.

The clearance letter arrives. The team floods the Slack channel with confetti emojis. The board sends congratulations. Someone books the celebratory dinner. For a few weeks, it feels like the hard part is over.

Then the calendar turns. The reps start dialing. And the market goes quiet.

No orders. No urgency. Hospitals that nodded along in discovery suddenly can't find budget, can't find a sponsor, can't find the meeting. The breakthrough device that cleared a brutal regulatory pathway is now sitting in a warehouse while the burn rate keeps climbing.

Here's the part nobody told you on celebration night: clearance was the regulatory finish line. It was never the commercial one.

The False Finish Line

FDA clearance proves your device is safe and effective. It does not prove a hospital will pay for it, that a surgeon will switch to it, or that a payer will reimburse it. Those are three entirely separate yeses, and the FDA controls none of them.

I've seen CEOs and founders pour two years and eight figures into the regulatory pathway, then treat commercialization as an afterthought — something the "sales hire" will sort out later. They built a clinical-grade product on top of a commercial vacuum. And the market can feel the vacuum immediately.

The cleared device doesn't fail because it's bad. It fails because no one engineered the conditions for anyone to buy it.

The Three Doors Nobody Warned You About

After clearance, your device has to walk through three doors. Each one can kill you on its own.

Reimbursement. If there is no code, no coverage, and no clear economic case, the hospital eats the cost of using your device. No CFO signs up to lose money on every procedure. You either map the reimbursement path before launch or you spend your runway discovering you don't have one.

The Value Analysis Committee. Most founders have never heard of the VAC until it quietly buries their deal. This is the cross-functional hospital committee that decides what actually gets purchased, clinicians, supply chain, finance, all in one room asking a single question: why should we add cost and risk to switch to you? A great clinical story is the price of admission. It is not the answer.

Market engineering. Adoption is not a feature of a good product. It is a system you build, positioning, the economic argument, the KOL strategy, the proof that de-risks the switch. Someone has to construct the reason the market moves. If you don't, the market stays exactly where it is: with your competitor.

You Cleared the Wrong Bar

This is the uncomfortable diagnosis I give clinical-stage teams: you optimized for the bar you could see and ignored the one that actually pays you.

Regulatory milestones are legible. There's a process, a submission, a decision. Commercial readiness is messier and easier to defer, so it gets deferred until the money is already spent and the stall is already here.

The teams that win don't treat go-to-market as a phase that begins after clearance. They build the commercial foundation in parallel with the regulatory one, so the day the letter lands, the reimbursement story, the VAC strategy, and the market argument are already standing.

That's the entire difference between a device that launches and a device that just exists.

Build the Foundation Before You Need It

If you're approaching clearance or you're already past it and watching the pipeline refuse to move, the problem almost certainly isn't your technology. It's that the commercial foundation underneath it was never engineered.

Building that foundation is only the beginning. Even the strongest positioning, reimbursement strategy, and commercial story won't create momentum if the market never hears it. Becoming the company hospitals, clinicians, investors, and strategic partners recognize requires consistent, strategic marketing that builds authority over time.

That's where Tribe's Marketing On Demand service comes in. We become your embedded marketing team, helping you translate complex innovation into clear market messaging, build thought leadership, create consistent content, and execute the marketing systems that keep your company visible long after clearance. Because great technology doesn't become best known by accident, it becomes best known through deliberate, sustained marketing.

Clearance gives you permission to enter the market. Strategic marketing is what makes the market remember your name.

Ready to build a brand the market can't ignore? Book a strategy call with Tribe Consulting to learn how our Marketing On Demand team can help you become the company your market knows, trusts, and chooses.